News

08 Nov 2017

REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services

Press release: REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services
Read More >>

08 Nov 2017

Visit REPROCELL at the “North East England Life Science Showcase” in Cambridge, MA (USA) on November 30, 2017

Visit REPROCELL at the “North East England Life Science Showcase” in Cambridge, MA (USA) on November 30, 2017
Read More >>

07 Nov 2017

Prof Stefan Przyborski to chair and speak at SMi Group’s 3D Cell Culture 2018 Conference

REPROCELL Europe Ltd's CSO Prof Stefan Przyborski to chair and speak at SMi Group’s 3D Cell Culture 2018 Conference
Read More >>

27 Sep 2017

Article by Dr David Bunton (co-authored) in the European Pharmaceutical Review, Autumn 2017

REPROCELL Europe Ltd’s CEO, Dr David Bunton, has co-authored an article titled New Strategy that has been published in the European Pharmaceutical Review, Autumn 2017. The article is in the EPR’s section, Applied Research, Development and Production. It is co-authored by David Bunton at REPROCELL Europe, Marian McNeil at Stratified Medicine Scotland and Pamela Brankin at Aridhia.
Read More >>

1 2 3 4 >>

Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins

13/05/2016

Proteon Therapeutics Announces Publication in Cardiovascular Pharmacology: Open Access Describing Promising Nonclinical Results for Vonapanitase in Improving Arteriovenous Fistula (AVF) Maturation and patency in Chronic Kidney Disease (CKD) Patients.

Proteon Therapeutics Inc. (Nasdaq:PRTO), a longstanding client of Biopta, is developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. Proteon today announced publication of additional nonclinical data on investigational drug vonapanitase in chronic kidney disease (CKD). The ex vivo study demonstrated that  vonapanitase removed elastic fibres from human cephalic veins in a dose-dependent manner, as assessed by both desmosine and histological staining of elastic fibres.
 
The study, titled Recombinant Human Elastase Treatment of Cephalic Veins, was published in Cardiovascular Pharmacology: Open Access. Proteons Senior Vice President and Chief Medical Officer, Steven Burke, M.D., is the senior author of the published manuscript. Dr Karen Bingham and Dr Emma Moss of Biopta were co-authors. The full paper can be accessed here

Live chat by BoldChat